D
Daraxoracib
Productby Revolution Medicines
Heard in 8 episodes across 7 shows since Aug 2026
Likely a mis-transcription of daraxonrasib, an investigational targeted cancer therapy being studied for tumors including pancreatic cancer.
Discussed inMarkets75%Politics25%
Episodes
8
across 7 shows
This week
0
episodes on 0 shows
Share of the conversation
Mentions of Daraxoracib per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Aug 27 | 0.01‰ | 1 |
| Sep 1 | 0.02‰ | 1 |
| Sep 3 | 0.02‰ | 1 |
| Oct 19 | 0.03‰ | 3 |
| Oct 20 | 0.03‰ | 1 |
| Nov 9 | 0.01‰ | 1 |
| Nov 15 | 0.02‰ | 2 |
| Nov 20 | 0.02‰ | 1 |
Email alert
Email me when Daraxoracib comes up on a podcast
One email a week at most, with the new episodes that mention Daraxoracib. Free, no account needed, unsubscribe in one click.
Episodes
8 episodes featuring Daraxoracib, newest first
- Nov 20, 2026
Britain and Europe test the limits of a post-Brexit resetGlobal News PodcastNov 20, 2026 - Nov 15, 2026
Biotech investors weigh gene editing, MASH data and RAS riskBreaking BiotechNov 15, 2026 - Nov 9, 2026
Biotech investors weigh obesity, RAS drugs and Moderna catalystsBreaking BiotechNov 9, 2026 - Oct 20, 2026
China reshapes biotech deals as RNAi reaches the brainBioCentury This WeekOct 20, 2026 - Oct 19, 2026
Cancer prevention meets the unfinished science of agingThe Peter Attia DriveOct 19, 2026 - Sep 3, 2026
AI spending strains markets as growth investors rethink riskEquity Mates Investing PodcastSep 3, 2026